<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736512</url>
  </required_header>
  <id_info>
    <org_study_id>U0597</org_study_id>
    <nct_id>NCT03736512</nct_id>
  </id_info>
  <brief_title>China Greenlight Registry Study (Post-market)</brief_title>
  <official_title>Prospective Registry of Outcomes With the GreenLight™ Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The duration of the study is expected to take approximately 3 years, which includes a
      recruitment period of approximately 12-months and 2 years (24-months) to complete procedure
      and follow-up visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study follow-up duration from the primary study procedure is 5 years.

        -  Baseline

        -  Study Procedure

        -  4-week

        -  6-month

        -  12-month

        -  24-month (End of Study) The study will be considered complete after all subjects have
           completed the 24-month follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The GreenLight XPS system provides durable relief of BPH symptoms in subjects.</measure>
    <time_frame>6-month follow up</time_frame>
    <description>Changes of IPSS Scores in subjects treated with the GreenLight XPS Laser System at 6 months</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber</intervention_name>
    <description>observational registry</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men diagnosed with benign prostatic hyperplasia (BPH) for whom GreenLight Laser therapy is
        recommended by their physician and eligible for inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided informed consent and agrees to attend all study visits

          -  Subject has a diagnosis of lower urinary tract symptoms due to benign prostatic
             enlargement causing bladder outlet obstruction

          -  Subject is able to complete self-administered questionnaires

          -  Clinical investigator has documented in the subject's medical record that in his/her
             judgment the subject is a surgical candidate for the PVP procedure

          -  Subject is ≥ 40 years of age

          -  Subject has an IPSS score greater than or equal to 12 measured at the baseline visit

          -  Subject has medical record documentation of a maximum urinary flow rate (Qmax) less
             than or equal to 15ml/s and sample is greater than or equal to 150ml (If uroflow
             testing documentation is available within 90 days prior to the informed consent date,
             and the sample is greater than or equal to 150ml, and the Qmax is less than or equal
             to 15ml/s it may be used for the inclusion/exclusion criteria)

          -  Subject has medical record documentation of a prostate volume of greater than or equal
             to 30 grams by transrectal ultrasound (TRUS))

        Exclusion Criteria:

          -  Subject has a life expectancy of less than 2 years

          -  Subject is classified as American Society of Anesthesiologists (ASA) V

          -  Subject is currently enrolled in, or plans to enroll in, any concurrent drug or device
             study unless preapproved by the sponsor

          -  Subject has an active infection that would preclude operation within 14 days of the
             study procedure (e.g., urinary tract infection or prostatitis)

          -  Subject has a diagnosis of, or has received treatment for, chronic prostatitis or
             chronic pelvic pain syndrome (e.g., non-bacterial chronic prostatitis)

          -  Subject has a neurogenic bladder or other neurological disorder that would impact
             bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injuries)

          -  Subject has a diagnosis of polyneuropathy (e.g., diabetic)

          -  Subject has diagnosis of stress urinary incontinence that requires treatment or daily
             pad/device use

          -  Subject has a diagnosis of prostate cancer or suspected prostate cancer based on PSA
             results and meeting the following:

        PSA level of 4 - 10 with an abnormal DRE (if biopsy collected must be positive); PSA level
        greater than 10 with a positive biopsy

          -  Subject has a history of CIS, TaGIII or any T1 stage bladder cancer

          -  Subject has damage to external urinary sphincter

          -  Subject has had an acute myocardial infarction, open heart surgery or cardiac arrest
             less than 180 days prior to the date of informed consent

          -  Subject is immunocompromised (e.g., organ transplant, leukemia)

          -  Subject currently or has a history of upper urinary tract stones

          -  Subject currently diagnosed with OAB and treated with medication If the subject does
             not carry a diagnosis but is suspected to have OAB, the investigator must use his/her
             discretion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men diagnosed with benign prostatic hyperplasia (BPH) for whom GreenLight Laser therapy is recommended by their physician and eligible for inclusion.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JIHONG QU</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YUWEI ZHANG</last_name>
    <phone>+86 10 85216440</phone>
    <email>Yuwei.Zhang@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hosptital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JIANG HUANG, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

